Cerebral venous thrombosis and heparin-induced thrombocytopenia in an 18-year old male with severe ulcerative colitis

Gudrun Scheving Thorsteinsson, Maria Magnussson, Lena M Hallberg, Nils Gunnar Wahlgren, Fredrik Lindgren, Petter Malmborg, Thomas H Casswall

Abstract

The risk of thromboembolism is increased in inflammatory bowel disease and its symptoms may be overlooked. Furthermore, its treatment can be complex and is not without complications. We describe a case of an adolescent boy who developed a cerebral sinus venous thrombosis during a relapse of his ulcerative colitis and who, while on treatment with heparin, developed heparin-induced thrombocytopenia (HIT). The treatment was then switched to fondaparinux, a synthetic and selective inhibitor of activated factor X.

Key words: Inflammatory bowel disease; Ulcerative colitis; Cerebral venous thrombosis; Heparin-induced thrombocytopenia; Fondaparinux

INTRODUCTION

Ulcerative colitis (UC) is a chronic inflammatory bowel disease (IBD) with unknown aetiology, which is localized in the colon. It affects both adults and children, and approximately 10% of the patients are diagnosed during childhood. Drugs used to induce its remission consist mainly of 5-aminosalicylic acid (5-ASA) and steroids, and 5-ASA as its maintenance therapy is often used. In more severe or steroid refractory cases, immune modulating therapy with azathioprine or 6-mercaptopurine, may be used, although the evidence for this is less convincing as compared to the treatment of Crohn's disease (CD). Despite intensive pharmacological treatment, relapse is not uncommon. Extra intestinal manifestations are reported to occur in about 40% of adult patients with UC. Figures for children are lower.

There are several risk factors for cerebral venous thrombosis (CVT), such as hormones (e.g. contraceptives and pregnancy), different kinds of hereditary thrombophilia and local factors including tumors. In childhood, other risk factors such as local head/neck infections, sepsis and dehydration due to systemic illness have been described. CVT is associated with a significant morbidity and mortality in children, and antithrombotic therapy with heparin in the acute phase followed by warfarin is recommended both in
children and in adults\textsuperscript{[8,9]}. However, CVT in children and adolescents with IBD is, only sparsely described. Hence, we describe a case of an adolescent boy who developed a cerebral sinus venous thrombosis during a relapse of his UC, and who, while on treatment with heparin, developed heparin-induced thrombocytopenia (HIT).

Written consent was received from the patient.

CASE REPORT

The patient was an 18-year old male who presented with extensive ulcerative colitis at the age of 12.5 years. He was initially treated with steroids and olsalazine. He went into remission within 3 mo. During the following years, it was complicated with several relapses, which were treated with repeated courses of prednisolone. Thus, two years after diagnosis, azathioprine (AZA) was started at a dosage of 1 mg/kg. His clinical condition was quite stable until the age of 17 years when an upper respiratory infection induced another relapse with worsening of the patient's general condition and a pronounced weight loss. A high dose of prednisolone (i.e., 40 mg daily) was restarted and the AZA dose was further increased (approximate 2 mg/kg). One month after the introduction of steroids, the patient developed unilateral peritonsillitis and was admitted to hospital for incision and intravenous penicillin G treatment. The dose of prednisolone was then tapered to 10 mg daily. The pharyngeal symptoms resolved and the patient was discharged on the third day. However, 5 d after discharge, he was readmitted due to a three-day history of severe headache, accompanied with nausea and vomiting. His colitis was clinically improved, apart from continuing daily episodes of loose stools.

The vital signs were normal. Neurological examination did not show any abnormalities or clinical signs of meningitis. During the first days after admission, the patient's headache deteriorated. A CT-scan of the head was performed and interpreted as normal. Hence, a lumbar puncture performed surprisingly revealed an intralumbar pressure of 49 cmH\textsubscript{2}O (< 20). The spinal fluid analyses were otherwise normal. An eye fundoscopy revealed bilateral papillodema and a diagnosis of pseudotumor cerebri induced by the steroid treatment was suspected. In order to reduce the cerebospinal pressure, 10 mL of cerebrospinal liquid was withdrawn. After an asymptomatic period of about 14 h, the patient's general appearance deteriorated with recurring severe headache.

Repeated neurological examinations did not reveal any focal symptoms. A magnetic resonance imaging of the brain (MRI) showed a CVT in the right sinus transversum and confluence area (Figure 1). D-dimer was clearly elevated. Treatment with intravenous heparin infusion was initiated with a loading dose of 5000 IU, followed by a continuous heparin infusion adjusted according to aPTT (approximately 27 IU/kg per hour) was required to maintain aPTT 2-3 times the baseline value). Despite an ongoing active colitis, anticoagulant therapy was considered safe.

In the following 7 d, the patient's general condition improved, although his appetite was poor and the blood-stained diarrhoea continued. Mild iron deficiency anaemia was noted, but vitamin B12 and homocysteine levels were normal. Parenteral nutrition was given as a nutritional support.

On day 7, warfarin was introduced under concomitant continuous heparin infusion. A rapid platelet count fall of 80% in 48 h was noted. Hence, azathioprine was temporarily stopped due to its known risk of thrombocytopenia. Heparin-induced thrombocytopenia (HIT) was suspected, warfarin was stopped and heparin infusion was switched to fondaparinux (Arixtra\textsuperscript{®}, GlaxoSmithKline). The starting dose of fondaparinux was 7.5 mg, which was tapered to 5 mg after 3 d. The diagnosis was later confirmed by the detection of IgG-antibodies against heparin with consistent criteria for HIT\textsuperscript{[8]}. The patient received a total of 6 units of platelet transfusion over a period of 4 d when the platelet count was < 18 × 10\textsuperscript{11}/L, due to the high expected risk of bleeding in this patient with colitis. Despite this, he had blood in his stools on several occasions during this period. The platelet count started to rise 7 d after heparin was stopped. When the platelet count reached > 80 × 10\textsuperscript{11}/L, azathioprine and warfarin were reintroduced and after 2 d of therapeutic INR between 2 and 3, fondaparinux was stopped after 9 d of treatment. The course of thrombocytopenia and medical intervention are presented in Figure 2.

During the course of CVT and HIT, a low dose of prednisolone and olsalazine was continued.

A follow-up CT scan 6 mo after the CVT diagnosis showed normal blood flow in all cerebral venous sini with no clinical neurological sequel.

A thorough work-up 7 mo after discharge showed that antithrombin, fibrinogen, lipoprotein (a), factor V gene mutation, prothrombin gene mutation, PAI-1, antiphospholipid antibodies, homocysteine, were all normal. Warfarin treatment was stopped after 8 mo of treatment. Thereafter, protein S, protein C, lupus anticoagulants, and FVII were tested normal.

The colitis eventually went into clinical and biochemical remission. The patient was hesitant to undergo another colonoscopy until 14 mo later, when the biopsies showed a mild diffuse inflammatory activity and some architectural mucosal changes.
The potential with UC than in CD patients and adolescents. Even death has been reported as a high risk of residual symptoms in affected children. It is important to raise the question about the increased risk of thromboembolism (TE) in patients with active IBD is well established with a 6.5% incidence of thrombosis or a 3-4 fold higher risk than in the general population. TE can also occur in the pediatric age group. The potential mechanisms underlying the prothrombotic state in IBD are hypercoagulation (elevated fibrinogen, decrease in antithrombin, protein S and protein C), hypofibrinolysis [elevated PAI-1 and lipoprotein (a)], platelet abnormalities, endothelial dysfunction (increased von Willebrand factor) and immunological abnormalities (antiphospholipid antibodies). The common genetic risk factors for TE factor V mutation (Factor V Leiden) and prothrombin mutation (G20210A) are not overrepresented in patients with TE and IBD compared to other patients with TE.

It has been suggested that hyperhomocysteinemia is a risk factor for vascular disease and a mediator of TE in adults and occurs more commonly in both pediatric and adult IBD patients than in healthy controls, which probably reflects the nutritional status with depleted levels of folate, cobalamin (B12) and pyridoxine (B6). The increased risk of TE in IBD associated with hyperhomocysteinemia is, however, questioned. Other acquired risk factors for TE that can affect patients with IBD are steroid treatment, surgery, immobilisation, dehydration, central venous catheters, iron deficiency and infections.

In our patient, the risk factors for the development of CVT were relapse of the disease, treatment with high doses of steroids and development of peritonsillitis, surgical incision, dehydration, and iron deficiency anemia. Despite the risk factors, the diagnosis of CVT was delayed mainly due to this complication which is rather rare. It is important to raise the question about sinus thrombosis in the request form to the radiology department since not only unenhanced CT, but also contrast CT needs to be performed for most cases.

Cerebral venous thrombosis is a rare, but serious complication of IBD and seems to be more common in UC than in CD patients. Its prognosis is variable with a high risk of residual symptoms in affected children and adolescents. Even death has been reported. The most frequent symptom is headache, which occurs in 75%-96% of patients. The headache is often severe and diffuse, usually preceding the appearance of neurological deficits. A combination of focal deficits, headache, seizures and altered consciousness is very suggestive of CVT. Apart from supportive care, anticoagulation therapy with heparin is the first line therapy for mild to moderate cases.Thrombolysis using recombinant tissue-type plasminogen activator (rt-PA) or urokinase has also been tried with various successes. Due to the potential risks, expert guidelines recommend that local thrombolysis using urokinase or rt-PA should be restricted to comatose patients or patients who deteriorate despite anticoagulant therapy.

HIT is defined as an immune-mediated side effect of heparin therapy, which causes a drop in platelet count of ≥ 50%.[20] HIT usually occurs after 5-10 d of heparin treatment, but a faster drop may be seen if heparin has been given earlier. Apart from thrombocytopenia, venous or arterial thrombosis can occur, even before thrombocytopenia. Other symptoms observed in children with HIT are acute thoracic pain, respiratory distress, anaphylactic shock and prolonged fever. An auto-immune response to platelet surface factor 4 (PF4) in complex with heparin is the major pathophysiological factor. These complexes lead to cellular activation and development of thrombocytopenia or thrombosis.[22] In children, this is probably as common as in adults. In a recent review by Risch and co-workers, the incidence of HIT in children is estimated to be 0%-2.3%.[21] Approximately 90 pediatric HIT cases have been reported in the literature until now. Children or neonates treated in intensive care units after cardiac surgery and adolescents treated with unfractionated heparin after thromboembolism constitute the highest risk of developing HIT in the pediatric population.[23]

Although a rapid increase in platelet levels after cessation of heparin is observed, stopping heparin, as a sole treatment, is not recommended since unfavourable outcome has been reported in over 40% of patients due to the risk of thrombosis. Hence, alternative anticoagulant therapy is recommended. Danaparoid (heparinoid) inhibits mainly factor Xa, and to a lesser extent prothrombin, lepirudin (thrombin inhibitor), and argatroban (thrombin inhibitor) are the recommended drugs for the treatment of HIT. Treatment of HIT with danaparoid has a risk of cross reactivity. Lepirudin and argatroban are expensive, administered as continuous intravenous infusion, and require frequent aPTT testing. However, for our patient, fondaparinux was used as anti-coagulant therapy. Fondaparinux is a synthetic and selective inhibitor of activated factor X (Xa), administered as subcutaneous injection once daily. The antithrombotic effect is achieved by a selective binding of fondaparinux to antithrombin, which increases 300-fold the endogenic neutralisation by antithrombin on factor Xa. Hence, it inhibits the production of thrombin and the development of thrombosis.[23] Fondaparinux does not appear to interact with HIT-related antibodies to induce platelet activity and aggregation according to in vitro tests and small clinical trials.[23]

For our patient, all potential future surgical
procedures and longer periods of immobilization should be accompanied with anti-embolic prophylactic treatment. However, due to his episode of HIT, heparin and low molecular weight heparin (LMWH) is contraindicated and alternative anticoagulant treatment must be used.

Patients with severe IBD are frequently treated with AZA, which may cause a problem during anticoagulant therapy for TE. Scarce reports are available on the AZA treatment which may interact with warfarin by diminishing its effect. Hence, the dose of warfarin may have to be increased 3–4 fold in order to achieve an optimal PK INR level[25].

Thromboembolic complications of IBD are not uncommon. If headache occurs during severe relapse of thromboembolism, CVT must be excluded. A CT scan with and without contrast is recommended as the first initial investigation. Platelet levels should be closely monitored during heparin treatment. When heparin is used, LMWH should be considered due to its lower risk of HIT than unfractionated heparin [24]. However, heparin has advantages in patients with a high risk of bleeding due to shorter T½. More studies concerning fondaparinux in treatment of patients with HIT are needed. It is necessary to evaluate the screening methods for identification of IBD patients with a high risk of thromboembolic complications. Furthermore, the efficacy and safety of prophylactic antithrombotic treatment of children with severe IBD must be evaluated in controlled clinical trials.

ACKNOWLEDGMENTS

The authors express their gratitude to Dr. Pia Petrini MD, Pediatric Coagulation Unit, Karolinska University Hospital for valuable comments, and Per Nydert, M. Sc. Pharm., Karolinska University Hospital Pharmacy, Stockholm, Sweden, for pharmacological details.

REFERENCES

1 Sawczenko A, Sandhu BK, Logan RF, Jenkins H, Taylor CJ, Mian S, Lynn R. Prospective survey of childhood inflammatory bowel disease in the British Isles. Lancet 2001; 357: 1093-1094
2 Sutherland L, Macdonald JK. Oral 5-amino salicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2006; (2): CD000545
3 Sands BE. Immunosuppressive drugs in ulcerative colitis: twisting facts to suit theories? Gut 2006; 55: 437-441
4 Ozdil S, Akyuz F, Pinarbası B, Demir K, Karaca C, Boztas G, Kaymakoglu S, Mungan Z, Besisik F, Cakaloglu Y, Okten A. Ulcerative colitis: analyses of 116 cases (do extraintestinal manifestations effect the time to catch remission?). Hepatogastroenterology 2004; 51: 768-770
5 Masuhr F, Mehraein S. Cerebral venous and sinus thrombosis: patients with a fatal outcome during intravenous dose-adjusted heparin treatment. Neurocrit Care 2004; 1: 355-361
6 Barnes C, Deveber G. Prothrombotic abnormalities in childhood ischaemic stroke. Thromb Res 2006; 118: 67-74
7 Manco-Johnson MJ. How I treat venous thrombosis in children. Blood 2006; 107: 21-29
8 Risch L, Fischer JE, Herklotz R, Huber AR. Heparin-induced thrombocytopenia in paediatrics: clinical characteristics, therapy and outcomes. Intensive Care Med 2004; 30: 1615-1624
9 Derdeyn CP, Powers WJ. Isolated cortical venous thrombosis and ulcerative colitis. AJNR Am J Neuroradiol 1998; 19: 488-490
10 Hasegawa H, Yokomori H, Tsuji T, Hirose R. Hemorrhagic cerebral sinus thrombosis in a case of controlled ulcerative colitis. Intern Med 2005; 44: 155
11 Musio I, Older SA, Jenkins T, Gregorie EM. Case report: cerebral venous thrombosis as a manifestation of acute ulcerative colitis. Am J Med Sci 1993; 305: 28-35
12 Tsujikawa T, Urabe M, Bamba H, Andoh A, Sasaki M, Koyama S, Fujiyama Y, Bamba T. Haemorrhagic cerebral sinus thrombosis associated with ulcerative colitis: a case report of successful treatment by anticoagulant therapy. J Gastroenterol Hepatol 2000; 15: 688-692
13 Umit H, Asil T, Celik Y, Tuzel A, Dokmeci G, Tuncbilek N, Utku U, Soylu AR. Cerebral sinus thrombosis in patients with inflammatory bowel disease: a case report. World J Gastroenterol 2005; 11: 5404-5407
14 Twigg G, Sandman-Goddard G, Szyper-Kravitz M, Shoenfeld Y. Systemic thromboembolism in inflammatory bowel disease: mechanisms and clinical applications. Ann N Y Acad Sci 2005; 1051: 166-173
15 Kao A, Dlugos D, Hunter JV, Mamula P, Thorarensen O. Anticoagulation therapy in cerebral sinovenous thrombosis and ulcerative colitis in children. J Child Neurol 2002; 17: 479-482
16 Danese S, Papa A, Saibeni S, Repici A, Malesci A, Vecchi M. Inflammation and coagulation in inflammatory bowel disease: The clot thickens. Am J Gastroenterol 2007; 102: 174-186
17 Nakano E, Taylor CJ, Chada L, McGaw J, Powers HJ. Hyperhomocysteinemia in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2003; 37: 586-590
18 Romagnuolo J, Fedorak RN, Dias VC, Bamforth F, Telscher M. Hyperhomocysteinemia and inflammatory bowel disease: prevalence and predictors in a cross-sectional study. Am J Gastroenterol 2001; 96: 2143-2149
19 Oldenburg B, Fijnheer R, van der Griend R, vanBerge-Henegouwen GP, Koningsberger JC. Homocysteine in inflammatory bowel disease: a risk factor for thromboembolic complications? Am J Gastroenterol 2000; 95: 2825-2830
20 Renowden S. Cerebral venous sinus thrombosis. Eur Radiol 2004; 14: 215-226
21 Risch L, Huber AR, Schmutte M. Diagnosis and treatment of heparin-induced thrombocytopenia in neonates and children. Thromb Res 2006; 118: 123-135
22 Poncz M, Rauova L, Cines DB. The role of surface PF4: glycosaminoglycan complexes in the pathogenesis of heparin-induced thrombocytopenia (HIT). Pathophysiol Haemost Thromb 2006; 35: 46-49
23 Kuo KH, Kovacs MJ. Fondaparinux: a potential new therapy for HIT. Hematology 2005; 10: 271-275
24 Savi P, Chong BH, Greinacher A, Gruel Y, Kelton JG, Warkentin TE, Eichler P, Meuleman D, Petitou M, Herault JP, Cariou R, Herbert JM. Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparin. Blood 2005; 105: 139-144
25 Havrdova DE, Rathbun S, Scheid D. A case report of warfarin resistance due to azathioprine and review of the literature. Pharmacotherapy 2001; 21: 355-357
26 Begelman SM, Hursting MJ, Aghababian RV, McCollum D. Heparin-induced thrombocytopenia from venous thromboembolism treatment. J Intern Med 2005; 258: 563-572

S-Editor Zhong XY L-Editor Wang XL E-Editor Lin YP